Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

75.48 -0.85 (-1.11%)
Streaming Delayed Price Updated: 11:12 AM EDT, Sep 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Halozyme Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a Compelling Case for Value Investors
Halozyme (HALO) presents a strong value investing case with low P/E ratios, robust financial health, high profitability, and solid growth, suggesting it trades below its intrinsic value. 
Via Chartmill
United Therapeutics Price Strength Rating Jumps After Its Stock Soared 33% Last Week On Positive Drug Test Results
United Therapeutics also boasts a terrific 96 Composite Rating. The Composite score combines five separate proprietary ratings into one. 
Via Investor's Business Daily
Topics ETFs
Halozyme Therapeutics Inc (NASDAQ:HALO) Fits Minervini's Trend Template with Strong Technicals and Earnings Momentum
Halozyme Therapeutics (HALO) exemplifies Mark Minervini's Trend Template, combining a strong technical uptrend with accelerating earnings growth and expanding profit margins. 
Via Chartmill
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Offers Affordable Growth With Strong Fundamentals
Discover HALOZYME (HALO), an affordable growth stock with strong profitability, solid financials, and a reasonable valuation. 
Via Chartmill
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Stands Out in Navellier's Growth Screen
HALOZYME (HALO) exemplifies Louis Navellier's growth investing strategy with strong sales growth, soaring earnings, high ROE, and consistent positive earnings surprises. 
Via Chartmill
Earnings Scheduled For August 5, 2025
 
Via Benzinga
Earnings Outlook For Halozyme Therapeutics
 
Via Benzinga
What's Driving the Market Sentiment Around Halozyme Therapeutics?
 
Via Benzinga
Argenx Stock Hits Record High After Reporting 664% Earnings Surge; This Rating Upgraded
Additionally, the IBD SmartSelect Composite Rating for Argenx stock rose from 94 to a near best 96 Tuesday. 
Via Investor's Business Daily
Topics ETFs
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Stands Out as a Top Undervalued Stock with Strong Fundamentals
Discover HALOZYME (HALO), a top value investing pick. It boasts a strong Valuation Rating of 9, high profitability, and robust growth, making it a fundamentally sound yet undervalued stock. 
Via Chartmill
What 7 Analyst Ratings Have To Say About Halozyme Therapeutics
 
Via Benzinga
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) – A Top Pick for Affordable Growth Investors
HALOZYME THERAPEUTICS (HALO) offers affordable growth with strong revenue, EPS expansion, and undervalued metrics, blending value and growth investing principles. 
Via Chartmill
What Does the Market Think About Halozyme Therapeutics?
 
Via Benzinga
Price Over Earnings Overview: Halozyme Therapeutics
 
Via Benzinga
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Fits Louis Navellier’s High-Growth Stock Criteria
Louis Navellier’s *The Little Book That Makes You Rich* outlines 8 key factors for identifying high-growth stocks like HALOZYME THERAPEUTICS (HALO), which excels in earnings, sales, margins, and ROE.... 
Via Chartmill
Halozyme (HALO) Q2 EPS Jumps 69%
Via The Motley Fool
Topics Intellectual Property
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Shows Strong Growth Momentum and Technical Breakout Potential
HALOZYME THERAPEUTICS INC (HALO) shows strong earnings growth, rising profit margins, and bullish technicals, making it a high-growth momentum stock to watch. 
Via Chartmill
Halozyme Therapeutics Inc (NASDAQ:HALO) Stands Out as a Strong Undervalued Stock with Solid Fundamentals
Halozyme Therapeutics (HALO) is an undervalued biotech stock with strong fundamentals, low P/E ratios, high profitability, and solid growth potential, making it a compelling pick for value investors. 
Via Chartmill
$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today
 
Via Benzinga
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - A Strong Contender in Affordable Growth Stocks
HALOZYME THERAPEUTICS (NASDAQ:HALO) shows strong growth, solid profitability, and reasonable valuation, making it an interesting affordable growth stock in the biotech sector. 
Via Chartmill
Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 15 Years
 
Via Benzinga
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - A Strong Candidate for Affordable Growth Investors
HALOZYME THERAPEUTICS (NASDAQ:HALO) offers strong growth, solid profitability, and reasonable valuation, making it a standout in affordable growth investing. 
Via Chartmill
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) – A Biotech Stock With Strong Fundamentals and Attractive Valuation
HALOZYME THERAPEUTICS (NASDAQ:HALO) offers a rare mix of strong growth, profitability, and financial health at an attractive valuation, making it a standout in the biotech sector. 
Via Chartmill
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) – A Strong Growth Stock with Technical Breakout Potential
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) shows strong growth fundamentals and a potential technical breakout, making it a stock to watch in the biotech sector. 
Via Chartmill
Here's How Much $100 Invested In Halozyme Therapeutics 15 Years Ago Would Be Worth Today
 
Via Benzinga
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - A Strong Candidate for Affordable Growth Investors
HALOZYME THERAPEUTICS (NASDAQ:HALO) offers strong growth, solid profitability, and an attractive valuation, making it a standout in the biotech sector for investors seeking affordable growth... 
Via Chartmill
Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 5 Years
 
Via Benzinga
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) – A Biotech Stock With Strong Fundamentals and Attractive Valuation
HALOZYME THERAPEUTICS (NASDAQ:HALO) offers strong profitability, financial health, and growth at an attractive valuation, making it a potential value opportunity in biotech. 
Via Chartmill
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
The Benzinga Stock Whisper Index highlights five stocks seeing increased interest from readers during the week and a look at what's drivin the interest. 
Via Benzinga
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - A Strong Candidate for Affordable Growth Investors
HALOZYME THERAPEUTICS (NASDAQ:HALO) offers strong growth, solid profitability, and an attractive valuation, making it a standout in the biotech sector for investors seeking affordable growth... 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.